David Ramsden of the Cystic Fibrosis Trust called this development a crucial step toward better treatments, crediting community advocacy for driving progress.

Ramsden emphasized that this approval signifies a move toward improved therapies for all CF patients, aiming to enhance their health outcomes.

NHS officials believe these treatments can significantly extend life expectancy and improve quality of life for individuals with cystic fibrosis.

John Stewart, NHS England’s director for specialised commissioning, highlighted that these therapies could reduce hospital visits and foster greater patient independence.

The National Institute for Health and Care Excellence (Nice) has approved Alyftrek, also known as vanza triple, for NHS use, marking a significant milestone in cystic fibrosis treatment.

Cystic fibrosis causes thick mucus buildup in the lungs and digestive system, leading to breathing difficulties and recurrent infections, which these new treatments aim to address.

Helen Knight from Nice highlighted that CFTR modulators are revolutionizing cystic fibrosis treatment, with Alyftrek showing significant benefits in clinical trials.

Alyftrek, or vanza triple, was approved for use in the UK earlier this year in March 2025, after showing comparable effectiveness to existing treatments.

Ludovic Fenaux from Vertex International described this approval as a major milestone in enhancing the lives of those with cystic fibrosis.

Alyftrek is specifically approved for patients with the most common form of cystic fibrosis and those with rare forms who previously lacked access to effective modulator therapy.

Modulator drugs like Alyftrek help the CFTR protein function effectively, which can dramatically improve life expectancy and quality of life for cystic fibrosis patients.

Clinical trials have demonstrated that Alyftrek is as effective as Kaftrio in improving lung function and maintaining respiratory health in CF patients.